Successful Management of Anti-TNF-Induced Psoriasis Despite Continuation of Therapy in a Pyoderma Gangrenosum Patient

Atrin Toussi, Stephanie T. Le, Virgina R. Barton, Chelsea Ma, Michelle Y. Cheng, Andrea Sukhov, Reason Wilken, Forum Patel, Elizabeth Wang, Emanual Maverakis

Research output: Contribution to journalArticle

Abstract

Pyoderma gangrenosum is an inflammatory, neutrophil-mediated disorder that is difficult to treat. Tumor necrosis factor and other inflammatory mediators are among the most promising therapeutic targets. We present a case of a 60-year-old woman with recalcitrant pyoderma gangrenosum treated with adalimumab, who paradoxically developed psoriasis. Secukinumab, an interleukin-17 inhibitor, was added to her regimen, resulting in successful treatment of her psoriasis. Secukinumab was later replaced by methotrexate, resulting in remission of both pyoderma gangrenosum and maintenance of a psoriasis-free state. We conclude that paradoxically induced psoriatic lesions can resolve with adjunct therapy despite continuation of anti-tumor necrosis factor agents. J Drugs Dermatol. 2020;19(2)199-201. doi:10.36849/JDD.2020.4662

Original languageEnglish (US)
Pages (from-to)199-201
Number of pages3
JournalJournal of drugs in dermatology : JDD
Volume19
Issue number2
DOIs
StatePublished - Feb 1 2020

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Successful Management of Anti-TNF-Induced Psoriasis Despite Continuation of Therapy in a Pyoderma Gangrenosum Patient'. Together they form a unique fingerprint.

  • Cite this